 |
|
Breast Cancer Trial Results
1. Osteoporosis Drug Raloxifene Does Not Protect Against Coronary Heart Disease, But Reduces Breast Cancer Risk
(Posted: 08/28/2006, Updated: 07/17/2008) - The drug raloxifene (Evista®) did not prevent heart problems in postmenopausal women with, or at high risk for, coronary heart disease, according to the July 13, 2006, issue of the New England Journal of Medicine.
2. Zoledronic Acid Improves Early Breast Cancer Treatment
(Posted: 06/19/2008) - The addition of zoledronic acid (Zometa) to adjuvant endocrine therapy in premenopausal women with early stage breast cancer significantly improves clinical outcomes beyond those achieved with endocrine therapy alone, according to findings presented at the 2008 ASCO meeting in Chicago.
3. Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
4. Paclitaxel Versus Docetaxel for Early Breast Cancer
(Posted: 04/30/2008) - Weekly treatment with the drug paclitaxel (Taxol®) in addition to standard chemotherapy proved most effective in extending overall survival among women with early-stage breast cancer, according to the April 17, 2008, New England Journal of Medicine.
5. Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial
(Posted: 03/26/2008) - Postmenopausal women taking the drug anastrozole (Arimidex®) to prevent a recurrence of breast cancer suffered more bone loss than women taking tamoxifen (Nolvadex®), even while anastrozole provided better protection against relapse, according to the March 1, 2008, Journal of Clinical Oncology.
1 2 3 4 Next >
|
|
|
